Glucocerebrosidase (Acid beta-glucosidase) (GBA)

Glucocerebrosidase (GBA) is a vital lysosomal enzyme responsible for the hydrolysis of glucocerebroside (also known as glucosylceramide) into glucose and ceramide [1]. Mutations in the GBA1 gene lead to a deficiency in this enzyme's activity, which is the underlying cause of Gaucher disease, a lysosomal storage disorder characterized by the accumulation of glucocerebroside in macrophages (Gaucher cells) [2]. This accumulation leads to clinical manifestations such as hepatosplenomegaly, cytopenia, and skeletal abnormalities. Furthermore, GBA1 mutations are recognized as the most significant genetic risk factor for the development of Parkinson's disease and Lewy body dementia, as enzyme dysfunction is linked to the impaired clearance of alpha-synuclein [3]. Therapeutic management typically involves enzyme replacement therapy (ERT) using recombinant versions of the enzyme, such as imiglucerase, to restore metabolic function, or substrate reduction therapies to balance the metabolic pathway [4][5]. Sources: [1] UniProt (P04062 - GBA_HUMAN) [2] NIH National Center for Advancing Translational Sciences (Gaucher Disease) [3] Parkinson's Foundation (GBA1 and Parkinson's) [4] FDA Drug Label: Cerezyme (Imiglucerase) [5] StatPearls: Gaucher Disease

Other names

GBA1GlucosylceramidaseAcid beta-glucosidaseGCaseLysosomal acid glucosylceramidaseGlucosylceramide beta-glucosidase

Enzyme replacement therapy (ERT) provides exogenous recombinant glucocerebrosidase to catalyze the hydrolysis of accumulated glucocerebroside in lysosomes [1][4]. Substrate reduction therapy (SRT) inhibits glucosylceramide synthase to decrease the rate of glucocerebroside synthesis [2]. Pharmacological chaperones bind to and stabilize mutant forms of the enzyme, facilitating proper folding and trafficking to the lysosome [3].